AARTI PHARMALABS LIMITED

Aarti Pharmalabs Limited submitted its Q1 FY27 Results Presentation, highlighting its position as a leading manufacturer of generic APIs and Xanthine derivatives. The company reported over 220 products and 63 patents filed, with a global market share in Xanthine estimated at 15-20%. The presentation detailed the company's operational revenue of INR 5,346 million for Q1 FY27, reflecting a 42.4% year-on-year increase. EBITDA for the same period was INR 1,327 million, with an EBITDA margin of 24.82%. The company emphasized its strong regulatory compliance, with multiple USFDA and EU GMP accreditations. Aarti Pharmalabs also outlined its strategic initiatives, including a planned investment of INR 149 crores for capacity expansion at its Atali Block. The document noted a focus on R&D investments to enhance product capabilities and a goal of achieving a revenue and EBITDA CAGR of 15-18% over the next 3-4 years.

The presentation emphasized strong growth and strategic initiatives.